<!-- FAIR USE of Zafirlukast.png: see image description page at http://en.wikipedia.org/wiki/Image:Zafirlukast.png for rationale -->Zafirlukast
is an oral leukotriene receptor antagonist
(LTRA) for the maintenance treatment of asthma
, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast
(Singulair), taken once daily. Zileuton
(Zyflo), also used in the treatment of asthma via its inhibition of 5-lipoxygenase, is taken four times per day.
Zafirlukast blocks the action of the cysteinyl leukotrienes
on the CysLT1 receptors
, thus reducing constriction of the airways
, build-up of mucus
in the lungs
of the breathing passages.
Zafirlukast is marketed by Astra Zeneca
with the brand names Accolate
, and Vanticon
. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Taiwan, Italy, Spain, Canada, Brazil, China and Turkey.
Healthy young men who received a single oral 40 mg dose attained peak plasma zafirlukast concentrations that averaged 607 μg/L at 3.4 hours. The elimination half-life ranged from 12 to 20 hours. In another study involving a 20 mg single oral dose in healthy men, the elimination half-life averaged 5.6 hours.Fischer JD, Song MH, Suttle AB, Heizer WD, Burns CB, Vargo DL, Brouwer KL.... Read More